Zhejiang East Asia Pharmaceutical

SHA-605177
Shanghai Stock Exchange
Healthcare Pharmaceuticals
Global Rank
#17801
Country Rank
#5433
Market Cap
294.34 M
Price
2.61
Change (%)
0.64%
Volume
1.24 M

SHA-605177's Next Dividend

Next Estimated Amount
¥0.327
Next Estimated Pay Date
07/24/2025
Last Amount
¥0.327
Last Pay Date
07/04/2024
Dividend Shot Clock Ex-Date: 07/04/2024
0
Days
0
Hours
0
Minutes
0
Seconds
Ex-dividend date passed

Zhejiang East Asia Pharmaceutical Dividend Chart

*Amounts are shown in the stock exchange currency (CNY) for convenience

Zhejiang East Asia Pharmaceutical(SHA-605177) Dividend History

Zhejiang East Asia Pharmaceutical (SHA-605177) currently pays an annual dividend of $0.00 per share, offering a dividend yield of 1.76%. The next dividend payout date has not been announced. With 2 consecutive years of dividend growth, Zhejiang East Asia Pharmaceutical has steadily increased its payout at an average annual rate of 12.63%, demonstrating a consistent commitment to rewarding investors.
Ex-Dividend Date Amount Adj. Amount Record Date Pay Date Change (%)
2024 ¥0.327 ¥0.327 13%
07/04/2024 ¥0.327 ¥0.327 n/a 07/04/2024 13%
2023 ¥0.29 ¥0.29 45%
06/15/2023 ¥0.29 ¥0.29 n/a 06/15/2023 45%
2022 ¥0.2 ¥0.2 -43%
06/08/2022 ¥0.2 ¥0.2 n/a 06/08/2022 -43%
2021 ¥0.35 ¥0.35
06/25/2021 ¥0.35 ¥0.35 n/a 06/25/2021
*Amounts are shown in the stock exchange currency (CNY) for convenience
*Historical information is adjusted for stock splits

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.